Replies to post #194724 on Biotech Values

[DewDiligence]

TRVN—…I want to see better data on addiction potential because if it still produces the high then my guess is it becomes more difficult to market (vs all the anti-abuse opioids).

In the acute, in-hospital setting, which TRVN is targeting, abuse deterrence should be less consequential than in the chronic setting.

I think the reduction of OIC for their oral drug would be a stronger driver [than reduction in respiratory distress]…

We can probably infer from the lack of discussion of OIC that TRV130 doesn’t confer a material benefit there.